MARKET

CFRX

CFRX

ContraFect
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.830
+0.250
+6.98%
After Hours: 3.780 -0.05 -1.31% 16:52 05/14 EDT
OPEN
3.580
PREV CLOSE
3.580
HIGH
3.910
LOW
3.560
VOLUME
351.20K
TURNOVER
--
52 WEEK HIGH
8.00
52 WEEK LOW
3.440
MARKET CAP
150.64M
P/E (TTM)
-2.5850
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 8h ago
Contrafect EPS beats by $0.11
Contrafect (CFRX): Q1 GAAP EPS of -$0.18 beats by $0.11.Cash, cash equivalents and marketable securities of $87.2M.Press Release
Seekingalpha · 8h ago
BRIEF-ContraFect Corp Reports Q1 Loss Per Share Of $0.18
reuters.com · 9h ago
ContraFect Q1 EPS $(0.18) Up From $(0.49) YoY
ContraFect (NASDAQ:CFRX) reported quarterly losses of $(0.18) per share. This is a 63.27 percent increase over losses of $(0.49) per share from the same period last year.
Benzinga · 9h ago
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 05/07 11:40
Maxim Group Thinks ContraFect’s Stock is Going to Recover
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to ContraFect (CFRX), with a price target of $14.00. The company's
SmarterAnalyst · 05/04 14:14
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical ...
GlobeNewswire · 05/03 12:30
BRIEF-ContraFect Corp Announces Issuance Of Composition Of Matter Patent For Cf-370 By United States Patent And Trademark Office
reuters.com · 05/03 12:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CFRX. Analyze the recent business situations of ContraFect through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CFRX stock price target is 14.33 with a high estimate of 23.00 and a low estimate of 6.50.
EPS
Institutional Holdings
Institutions: 92
Institutional Holdings: 24.62M
% Owned: 62.59%
Shares Outstanding: 39.33M
TypeInstitutionsShares
Increased
8
2.17M
New
8
519.76K
Decreased
10
323.84K
Sold Out
3
28.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/President/Chief Executive Officer/Director
Roger Pomerantz
Vice Chairman/Director
Steven Gilman
Chief Financial Officer/IR Contact Officer
Michael Messinger
Executive Vice President
Cara Cassino
General Counsel/Secretary
Natalie Bogdanos
Lead Director
Sol Barer
Independent Director
Lishan Aklog
Independent Director
Jane Barlow
Independent Director
David Low
Independent Director
Michael Otto
Independent Director
Cary Sucoff
No Data
About CFRX
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.

Webull offers kinds of ContraFect Corp stock information, including NASDAQ:CFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CFRX stock methods without spending real money on the virtual paper trading platform.